Feb 27 |
Fulcrum Therapeutics files for $350M mixed shelf
|
Feb 27 |
Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript
|
Feb 27 |
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
|
Feb 27 |
Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023
|
Feb 27 |
Fulcrum Therapeutics GAAP EPS of -$0.40 beats by $0.04, revenue of $0.87M beats by $0.48M
|
Feb 27 |
Fulcrum Therapeutics Announces Recent Business Highlights and Financial ResultsĀ for Fourth Quarter and Full Year 2023
|
Feb 26 |
Fulcrum Therapeutics Q4 2023 Earnings Preview
|
Feb 20 |
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
|
Feb 11 |
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after 31% loss over the past year
|
Feb 6 |
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|